Healthcarewriter

Global Contraceptive Drugs Market is anticipated to grow at a CAGR of 4.32% by 2027 | DelveInsight Estimates

Contraceptive drugs are medication with the primary action to avoid conception by preventing the fusion of the gametes by employing different techniques such as the inhibition of follicular development, ovulation which is followed majorly in oral contraceptive pills, as well as the making the environment hostile for the sperms to survive as followed by spermicidal products.

DelveInsight’s Contraceptive Drugs Market Insights and Forecast report provides the current and forecasted Contraceptive Drugs Market forecasts for next five years, upcoming innovation in individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Contraceptive Drugs Market.

To know more about the Contraceptive Drugs Market Report, click here: https://www.delveinsight.com/report-store/contraceptive-drugs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of the Contraceptive Drugs Market are:

Global contraceptive drugs market was valued at USD 8.59 billion in 2021, growing at a CAGR of 4.32% during the forecast period from 2022 to 2027 to reach USD 11.04 billion by 2027.
As per the data provided by the World Health Organization (2022), 4 million women living in low and middle-income countries have unintended pregnancies annually across the globe.
The United Nation’s Department of Economic and Social Affairs 2019 statistics mentioned that approximately 922 million women of reproductive age (or their partners) use contraception methods comprising various products of which contraceptive pills are one of the most common and reliable sources for avoiding unintended pregnancies.
Some of the key market players operating in the contraceptive drugs market includes Abbvie Inc, BAYER AG, Viatris Inc, Gedeon Richter Plc., Agile Therapeutics, Evofem Biosciences, Inc., Amneal Pharmaceuticals LLC., Pfizer Inc, Hana, Maxwellia Ltd., Piramal Enterprises, Mankind Pharma, HLL Lifecare Limited, Theramex, Besins Healthcare, Marlborough Pharmaceuticals, Teva Pharmaceuticals USA, Inc, and others

Request for free sample to know more about the Contraceptive Drugs Market facts: https://www.delveinsight.com/report-store/contraceptive-drugs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key market players operating in the contraceptive drugs market includes

Abbvie Inc
BAYER AG
Viatris Inc
Gedeon Richter Plc.
Agile Therapeutics
Evofem Biosciences, Inc.
Amneal Pharmaceuticals LLC.
Pfizer Inc
Hana
Maxwellia Ltd.
Piramal Enterprises
Mankind Pharma
HLL Lifecare Limited
Theramex
Besins Healthcare
Marlborough Pharmaceuticals
Teva Pharmaceuticals USA, Inc
And others

To know more about the Contraceptive Companies working in the Drug Market, click here: https://www.delveinsight.com/sample-request/contraceptive-drugs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Recent Developmental Activities in Contraceptive Drugs Market:

• In May 2020, the US FDA approved Phexxi™ (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females with reproductive potential.

• Bayer and Daré Bioscience entered into an exclusive license agreement for the US commercial rights to investigational hormone-free, monthly contraceptive Ovaprene® in January 2020. As per this agreement, Bayer may commercialize Daré’s investigational contraceptive product, Ovaprene® in the United States once approved by the FDA.

• Gedeon Richter Plc. signed an asset purchase agreement with Janssen Pharmaceutica NV on December 2020, in respect of Janssen’s Outside US Evra® transdermal contraceptive patch assets. The transaction amounted to approximately around USD 263.5 million.

Know more about the recent developments in Contraceptive Drugs Market by downloading the sample page, click here: https://www.delveinsight.com/report-store/contraceptive-drugs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Contraceptive Drugs Market Report:

Study Period: 2019-2027
Base Year: 2021
Forecast Period: 2022-2027
Contraceptive Drugs Market By Product Type (Oral Contraceptive Pills [Combination And Progestin-Only], Injectables, Topical Contraceptives [Gels & Jellies, Patches, And Creams])
Contraceptive Drugs Market By Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, And Others)
Contraceptive Drugs Market By geography ((North America, Europe, Asia-Pacific, and Rest of the World)
Contraceptive Drugs Companies: Abbvie Inc, BAYER AG, Viatris Inc, Gedeon Richter Plc., Agile Therapeutics, Evofem Biosciences, Inc., Amneal Pharmaceuticals LLC., Pfizer Inc, Hana, Maxwellia Ltd., Piramal Enterprises, Mankind Pharma, HLL Lifecare Limited, Theramex, Besins Healthcare, Marlborough Pharmaceuticals, Teva Pharmaceuticals USA, Inc, and others

DelveInsight’s Analysis: Global contraceptive drugs market was valued at USD 8.59 billion in 2021, growing at a CAGR of 4.32% during the forecast period from 2022 to 2027 to reach USD 11.04 billion by 2027.

Click here to know more about the Scope of the Contraceptive Drugs Market Report: https://www.delveinsight.com/report-store/contraceptive-drugs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents:

1. Contraceptive Drugs Market Report Introduction

2. Contraceptive Drugs & Market Executive Summary

3. Regulatory Analysis

4. Contraceptive Drugs Market Key Factors Analysis

5. Contraceptive Drugs Market Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Contraceptive Drugs Market

7. Contraceptive Drugs Market Layout

8. Contraceptive Drugs Market Global Company Share Analysis; Key 3-5 Companies

9. Contraceptive Drugs Market Company and Product Profiles

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

Request for Detailed TOC: https://www.delveinsight.com/sample-request/contraceptive-drugs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Latest Report:

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Dental Implants and Prosthesis Market is Anticipated to Progress at a Substantial CAGR of 7.79% by 2027, Analyzes DelveInsight

DelveInsight’s Dental Implants and Prosthesis Market Insights and Forecast report provides the current and forecast Dental Implants and Prosthesis, upcoming innovations in the devices, individual market shares of the devices, challenges, drivers, and barriers, market trends, and key competitors in the Dental Implants and Prosthesis Market scenario.

Some of the essential takeaways from the Dental Implants and Prosthesis Market report:

According to DelveInsight analysis, North America is expected to dominate the overall Dental Implants and Prosthesis Market during the forecasted period.
Key Dental Implants and Prosthesis companies proactively working in the market include Fresenius SE & Co. KgaA, Boston Scientific Corporation, Cook Medical, Inc., Cardinal Health Inc., Becton, Dickinson, and Company, Moog Inc., B. Braun Melsungen AG, Amsino International, Inc., Nestlé Health Science, Avanos Medical, Inc., Abbott Laboratories, CONMED Corporation, CORPAK, Covidien PLC, ALCOR Scientific Inc., Applied Medical Technology, Inc., Vygon, Danone, Enteral Access Technologies Ltd., Medline Industries, LP, among others.
As per DelveInsight estimates, the Global Dental Implants and Prosthesis Market size was valued at USD 10.42 Billion in 2021, growing at a CAGR of 7.79% during the forecast period from 2022 to 2027, to reach USD 16.35 Billion by 2027.
On January 17, 2022, Renew, LLC and Western Dental & Orthodontics entered into a strategic partnership to make high-quality implant-supported removable anchored dentures surgical centers in California and Texas.
On January 17, 2022, Yomi, a robot-assisted surgical device developed by the healthcare start-up Neocis, gained FDA clearance for general dental implant procedures in 2016 and full-arch dental implant procedures in 2020. Since its development, Yomi has become increasingly popular, and its manufacturer has recently announced that clinicians have already placed over 10,000 dental implants using the dental robotic platform.
On June 08, 2021, Neoss announced the launch of NeossONE™. NeossONE™ is a solution unique to the Neoss® Implant System – one prosthetic platform, across three implant ranges, including ALL implant diameters and abutments.

To pick on the latest highlights related to Enteral Feeding Procedures get the snapshot of the key highlights entailed in the Dental Implants and Prosthesis Market Sample Report

View Report: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Dental Implants and Prosthesis Overview

Dental Implants are artificial roots that look like a tooth or teeth. These substitutes for missing teeth are placed into the jaw to support restorations. Prosthesis involves the reconstruction of missing teeth with the use of crowns, bridges, implants, and dentures.

Dental Implants and Prosthesis Market Insight

Geographically, the Global Dental Implants and Prosthesis market is studied for North America, Europe, Asia-Pacific, and the Rest of the World. In terms of revenue share, North America is expected to dominate the overall Dental Implants and Prosthesis market during the forecast period. This domination is owing to the rising burden of the geriatric population in the region suffering from dental disorders, the rising prevalence of various dental diseases such as edentulism, and technologically advanced devices in the product arena will bolster the growth of the North America Dental Implants and Prosthesis market.

Furthermore, the presence of key manufacturers such as Nobel Biocare Services AG (Danaher Corporation), Straumann Holding AG, Dentsply Sirona, among others active in the production of Dental Implants and Prosthesis is anticipated to fuel the market in the region. Moreover, the occurrence of various strategic business activities in the region such as company collaborations, acquisitions, product launches, and approval, among others are also expected to propel the market for Dental Implants and Prosthesis in the region.

View Report: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Learn more about the Several Types of Dental Implants and Prosthesis @ Dental Implants and Prosthesis Assessment

Dental Implants and Prosthesis Market Dynamics

Owing to certain factors such as the growing burden of the geriatric population who are susceptible to developing various dental disorders, the rising prevalence of various dental diseases due to poor eating habits, lack of oral hygiene, and accidents that causes tooth loss across the globe are some of the factors likely to boost the Dental Implants and Prosthesis market. In addition, accumulative focus on developing technologically advanced devices in the product arena will contribute a lot to the Global Dental Implants and Prosthesis Market. Furthermore, Dental Implants and Prosthesis have become an important tool, as they are minimally invasive surgical procedures for dental and cosmetic applications, and the rising adoption of computer-aided design/computer-aided manufacturing (CAD/CAM) technologies for implants have led to producing simplified and accurate implants components, all the aforementioned factors are expected to augment the global market for Dental Implants and Prosthesis.

However, the high cost of the implants and some of the dental treatments which are not covered under health coverage is likely to impede the Dental Implants and Prosthesis market. Also, the unprecedented COVID-19 pandemic has had a substantial effect on the Dental Implants and Prosthesis Market

To gain a better understanding of the COVID-19 impact on Dental Implants and Prosthesis, get a snapshot of the Dental Implants and Prosthesis Market Impact by COVID-19

View Report: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Scope of the Dental Implants and Prosthesis Market Report

Coverage: Global
Study Period: 2022-2027
Market Segmentation By Material: Titanium Implants, Zirconium Implants
Market Segmentation By Design: Tapered Dental Implants, Parallel-Walled Dental Implants
Market Segmentation By Types: Endosteal Implants, Subperiosteal Implants, Others
Market Segmentation By Prosthesis/Products: Dentures, Crown, Bridges, Veneer, Abutment, Inlays & Onlays
Market Segmentation By End-User: Hospitals, Dental Clinics, Others
Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views and Analyst’s View

Delveinsight Analysis: Global Dental Implants and Prosthesis Market was valued at USD 10.42 Billion in 2021, growing at a CAGR of 7.79% during the forecast period from 2022 to 2027, to reach USD 16.35 Billion by 2027.

View Report: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Table of Contents

1	Report Introduction
2	Executive summary
3	Regulatory and Patent Analysis
4	Dental Implants and Prosthesis Market Key Factors Analysis
5	Dental Implants and Prosthesis Market Porter’s Five Forces Analysis
6	COVID-19 Impact Analysis on Dental Implants and Prosthesis Market
7	Dental Implants and Prosthesis Market Layout
8	Dental Implants and Prosthesis Market Global Company Share Analysis – Key 3-5 Companies
9	Dental Implants and Prosthesis Company and Product Profiles
10	Project Approach
11	KOL Views
12	DelveInsight Capabilities
13	Disclaimer
14	About DelveInsight

View Report: https://www.delveinsight.com/report-store/dental-implants-and-prosthesis-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Latest Report:

About DelveInsight

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Global Menopause Market is anticipated to grow at a CAGR of 7.10% by 2027 | DelveInsight Estimates

DelveInsight’sMenopause Market Insights and Forecast report provides the current and forecast of Menopause, upcoming innovations, individual market shares of the products, challenges, drivers, and barriers, market trends, and key competitors in the Menopause Market scenario.

Some facts of the Menopause Market Report:

Global menopause market was valued at USD 15.53 billion in 2021, growing at a CAGR of 7.10% during the forecast period from 2022 to 2027 to reach USD 23.44 billion by 2027.
The demand for products that help in management of menopause symptoms is witnessing a surge majorly due to the rising female aging population wherein age plays a prominent role in regulating menstrual cycle and the growing awareness regarding menopause among people. Thereby boosting the growth of the menopause market during the forecast period from 2022-2027.
As per the figures quoted by the World Health Organization (WHO) in their Decade of Healthy Ageing (2020–2030) Report, the people in the age group of 60 years and above will account for a 34% higher share in the total population growing from one billion in 2019 to 1.4 billion in 2030.
For instance, as per the facts provided by the United Nations Fund for Population Activities (2021), it has been estimated that by 2050, the older population in the APAC region would reach to 1.3 billion, out of which 53% of the total population share would be accounted for by the females.
Some of the companies working in Menopause Market are ISIDEN, Novapharm, Arkopharma, Pileje, Thermamex, ÉLERTÉ Laboratories, Serelys Pharma, Besins Healthcare, Bayer, ITALFARMACO S.p.A, Pfizer Inc, Mylan NV, Teva Pharmaceuticals, TherapeuticsMD, Inc , Novo Nordisk, Novartis, Millicent Pharma, PADAGIS LLC, Vertical Pharmaceuticals LLC, Amgen and Others.

To know more facts about Menopause Market Research Report, Click Here: Menopause Market Assessment

View Report: https://www.delveinsight.com/report-store/menopause-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Recent Developmental Activities in Menopause Market:

In September 2021, Theramex received the regualatory approval for Bijuva® / Bijuve® (1mg estradiol / 100mg progesterone) across Europe and the UK. It is the first, and only, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in post-menopausal women with intact uterus and to be administered orally.
In April 2019, Amgen and UCB (Euronext Brussels: UCB) received the regulatory approval from the U.S. Food and Drug Administration (FDA) for EVENITY™ (romosozumab-aqqg) which is intended for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

Know more in detail about the recent developmental activities: Menopause Treatment Landscape

View Report: https://www.delveinsight.com/report-store/menopause-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Menopause Companies:

ISIDEN, Novapharm, Arkopharma, Pileje, Thermamex, ÉLERTÉ Laboratories, Serelys Pharma, Besins Healthcare, Bayer, ITALFARMACO S.p.A, Pfizer Inc, Mylan NV, Teva Pharmaceuticals, TherapeuticsMD, Inc , Novo Nordisk, Novartis, Millicent Pharma, PADAGIS LLC, Vertical Pharmaceuticals LLC, Amgen

To get free access to Detailed information on Menopause Market Analysis, Click here: Menopause Companies and Product

View Report: https://www.delveinsight.com/report-store/menopause-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Scope of the Menopause Market Report

Study Period: 2019 – 2027
Base Year: 2021
Forecast Period: 2022 – 2027
By Treatment Type (Hormonal Products, Non-Hormonal Products, And Dietary Supplements)
By Distribution Channel (Hospitals, Retail, And Online Pharmacies)
By Geography (North America, Europe, Asia-Pacific, and Rest of the World).
Delveinsight Analysis: Global menopause market was valued at USD 15.53 billion in 2021, growing at a CAGR of 7.10% during the forecast period from 2022 to 2027 to reach USD 23.44 billion by 2027.

Get free Access to the Menopause Sample Pages, Click here: Menopause Sample Report

View Report: https://www.delveinsight.com/report-store/menopause-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Table of Contents:

1. Menopause Market Report Introduction

2. Menopause Market Executive Summary

3. Regulatory Analysis

4. Menopause Market Key Factors Analysis

5. Menopause Market Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Menopause Market

7. Menopause Market Layout

8. Menopause Market Global Company Share Analysis & Key 3-5 Companies

9. Menopause Market Company and Product Profiles

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

View Report: https://www.delveinsight.com/report-store/menopause-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr

Latest Report:

About DelveInsight

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Adult Growth Hormone Deficiency Market Size, Epidemiology, Pipeline, Therapies, Companies and Competitive Analysis by DelveInsight

Adult Growth Hormone Deficiency (AGHD) is a medical condition that occurs when the pituitary gland in brain does not produce enough growth hormone. Most cases of Adult Growth Hormone Deficiency (AGHD) result from damage to the pituitary gland caused by a pituitary tumor or by treatment for this using surgery and/or radiotherapy. Adult Growth Hormone Deficiency (AGHD) is treated with growth hormone replacement therapy. The growth hormone that is used is an artificial preparation that individuals can administer themselves.

DelveInsight’s “Adult Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Adult Growth Hormone Deficiency, historical and forecasted epidemiology as well as the Adult Growth Hormone Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of Adult Growth Hormone Deficiency Market are:

According to D B Allen et al., about 15%-20% of the cases represent the transition of childhood GH deficiency into adulthood.
As per Jana Bujanova et al., estimates prevalence of AGHD in the UK is approximately 1 in 10 000 (a total of approximately 6380 patients). If Childhood-onset GH deficiency is added to this number then prevalence is 1 in 10 000 to 1 in 3500.
In a study, the author found that a greater proportion of Japanese adults had AO GHD than CO GHD, a finding similar to those of previous studies in Caucasian adults. In contrast, in a previous study of Japanese adults with GHD, only 45% of participants were reported to have AO GHD. That study, however, included a smaller number of participants than were included in the study and was conducted at a single institution. [Akira Shimatsu et al.,2011]
Adult Growth Hormone Deficiency is more common among males than females.

Scope of the Adult Growth Hormone Deficiency MarketReport

The report covers the descriptive overview of Adult Growth Hormone Deficiency, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.
Comprehensive insight has been provided into the Adult Growth Hormone Deficiency epidemiology and treatment in the 7MM.
Additionally, an all-inclusive account of both the current and emerging therapies for Adult Growth Hormone Deficiency is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of the Adult Growth Hormone Deficiency market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Adult Growth Hormone Deficiency market.

Some of Adult Growth Hormone Deficiency Companies are:

Novo Nordisk
Ascendis Pharma
And Many Others

Some of Adult Growth Hormone Deficiency Therapies are:

Sogroya (somapacitan-beco)
TransCon hGH
And Many Others

Table of Contents:

1. Key Insights

2. Executive Summary of Adult Growth Hormone Deficiency

3. Competitive Intelligence Analysis for Adult Growth Hormone Deficiency

4. Adult Growth Hormone Deficiency: Market Overview at a Glance

5. Adult Growth Hormone Deficiency: Disease Background and Overview

5.1. Introduction

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Adult Growth Hormone Deficiency Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Adult Growth Hormone Deficiency: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Adult Growth Hormone Deficiency

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for Detailed TOC: https://www.delveinsight.com/sample-request/acanthamoeba-keratitis-market

Some of Newly Launched Report:

Related Blogs:

About Delveinsight:

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Chronic Idiopathic Urticaria Market Size, Epidemiology, Pipeline, Therapies, Companies and Competitive Analysis by DelveInsight

Chronic idiopathic urticaria (CIU) is a distressing skin condition that causes red, swollen, itchy and sometimes painful hives or “wheals” on the skin. It is being associated with autoimmunity in almost half of the cases but the remaining cases still remains “idiopathic” and all are considered spontaneous. Therefore, the term chronic spontaneous urticaria (CSU) has been employed to indicate chronic urticaria that is endogenous, and independent of any external physical stimulus, which is conceptually helpful, and does not imply knowing or not-knowing the cause.

DelveInsight’s “Chronic Idiopathic Urticaria Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Chronic Idiopathic Urticaria, historical and forecasted epidemiology as well as the Chronic Idiopathic Urticaria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of Chronic Idiopathic Urticaria Market are:

According to the study by Zuberbier T et al., 2010; lifetime prevalence for Chronic Urticaria was 1.8%. Women were more likely than men to have Chronic Urticaria (70.3% vs. 29.7%). The lifetime prevalence of urticaria: 7.8% (Germany). The estimates in the existing literature for the prevalence of CU range from 0.05% to 3%.
According to the study of Reham Ezz El-Dawla El-Sharkawy et al., 2018; the incidence of CU has been estimated at 1.4% per year in the USA with male to female ratio at 1: 3.7. Out of 108 patients, 58.3% were affected with CSU.
According to the study by Marcus Maurer et al., 2017; the estimated point prevalence of CIU is approximately 0.5% to 1% worldwide.
The first-line management of acute or chronic urticaria is focused on the use of H1 antihistamines, leukotriene antagonists and/or H2 receptor antagonists next. However, in Europe, treatment with sedating H1 antihistamines and H2 antihistamines are not recommended. Along with these there are few FDA approved therapy for treatment of CIU.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/chronic-idiopathic-urticaria-market

Scope of the Chronic Idiopathic Urticaria MarketReport

The report covers the descriptive overview of Chronic Idiopathic Urticaria, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.
Comprehensive insight has been provided into the Chronic Idiopathic Urticaria epidemiology and treatment in the 7MM.
Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Idiopathic Urticaria is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of the Chronic Idiopathic Urticaria market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Idiopathic Urticaria market.

Some of the Chronic Idiopathic Urticaria Companies are:

Novartis
Genentech
Kiniksa pharmaceuticals
UCB Inc.
Merck Sharp & Dohme Corp.
Sanofi-aventis
And Many Others.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/chronic-idiopathic-urticaria-market

Chronic Idiopathic Urticaria Drugs:

Xolair (omalizumab)
XYZAL (levocetirizine dihydrochloride)
CLARINEX (Desloratadine)
Allegra (fexofenadine hydrochloride)
Ligelizumab
And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/chronic-idiopathic-urticaria-market

Table of Contents:

1. Key Insights

2. Executive Summary of Chronic Idiopathic Urticaria

3. Competitive Intelligence Analysis for Chronic Idiopathic Urticaria

4. Chronic Idiopathic Urticaria: Market Overview at a Glance

5. Chronic Idiopathic Urticaria: Disease Background and Overview

5.1. Introduction

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Chronic Idiopathic Urticaria Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Chronic Idiopathic Urticaria: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Chronic Idiopathic Urticaria

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for Detailed TOC: https://www.delveinsight.com/sample-request/chronic-idiopathic-urticaria-market

Some of Newly Launched Report:

Related Blogs:

About Delveinsight:

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Acanthamoeba Keratitis Market Size, Epidemiology, Pipeline, Therapies, Companies and Competitive Analysis by DelveInsight

Acanthamoeba Keratitis (AK) is a rare but serious infection of the eye that can result in permanent visual impairment or blindness. This infection is caused by a microscopic, free-living ameba (a single-celled living organism) called Acanthamoeba. The organism causes AK when it infects the transparent outer covering of the eye called the cornea. The condition is very common in nature and can be found in water bodies (for example, lakes and oceans), soil, and air.

DelveInsight’s “Acanthamoeba Keratitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Acanthamoeba Keratitis, historical and forecasted epidemiology as well as the Acanthamoeba Keratitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of Acanthamoeba Keratitis Market are:

As per a study conducted by Abelson et al. (2008), an estimated 5,000 cases of Acanthamoeba keratitis have occurred in the United States as of 2006, but since AK is so commonly misdiagnosed and the disease does not need to be reported to the Centers for Disease Control and Prevention, the actual number could be much higher. Approximately 88% of contact lens-related AK cases occur in soft contact lens wearers and 12% in rigid lens wearers.
According to the studies it has been estimated that the disease affect male and female equally.
According to Kozak et al. (2020), over 80% of Acanthamoeba keratitis appears in contact lens wearers. In one study, 75% of the patients were contact lens wearers; 40% wore daily soft lenses, 22% wore rigid gas permeable lenses, and 38% wore extended wear or other lenses.
According to Booton et al. (2009), the genotype of 15 Acanthamoeba sp. isolates from AK cases from this outbreak using sequence analysis of a region of the 18S rDNA were determined. The results indicated that the isolates were predominantly genotype T4 (87%), with the remaining isolates being genotype T3 (13%). Both genotypes had previously been observed in AK cases.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/acanthamoeba-keratitis-market

Scope of the Acanthamoeba Keratitis MarketReport

The report covers the descriptive overview of Acanthamoeba Keratitis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.
Comprehensive insight has been provided into the Acanthamoeba Keratitis epidemiology and treatment in the 7MM.
Additionally, an all-inclusive account of both the current and emerging therapies for Acanthamoeba Keratitis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of the Acanthamoeba Keratitis market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acanthamoeba Keratitis market.

Some of the Acanthamoeba Keratitis Companies are:

Polihexanide (PHMB)
And Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/acanthamoeba-keratitis-market

Acanthamoeba Keratitis Drugs:

SIFI
And Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/acanthamoeba-keratitis-market

Table of Contents:

1. Key Insights

2. Executive Summary of Acanthamoeba Keratitis

3. Competitive Intelligence Analysis for Acanthamoeba Keratitis

4. Acanthamoeba Keratitis: Market Overview at a Glance

5. Acanthamoeba Keratitis: Disease Background and Overview

5.1. Introduction

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Acanthamoeba Keratitis Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Acanthamoeba Keratitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Acanthamoeba Keratitis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for Detailed TOC: https://www.delveinsight.com/sample-request/acanthamoeba-keratitis-market

Some of Newly Launched Report:

Related Blogs:

About Delveinsight:

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

DelveInsight’s Trending Reports 2022: Chondrosarcoma Market, Microsatellite Stable Colorectal Cancer Market, Rituximab Biosimilars Insight, Pain Management Devices Market, 22q11.2 Deletion Syndrome Market.

Chondrosarcoma Market

Chondrosarcoma is a bone sarcoma that develops in the cartilage cells. It mostly affects adults above the age of 40 and the most common sites are the upper arm, pelvis and thigh bone. Chondrosarcomas can be subdivided in several ways: by histologic grade, whether they arise de novo (primary) or from benign lesions (secondary), by location within the bone (central or peripheral), or by syndrome.

Some of the facts:

According to the US Surveillance, Epidemiology and End Results Program, Chondrosarcomas contribute 30% among different types of bone cancer.
Chondrosarcomas develops most often in adults, with an average age at diagnosis of 51. Less than 5% of cases occur in patients younger than 20.
Chondrosarcoma is a tumor of adulthood and older age. The majority of patients are older than 50 years of age at diagnosis, with a slight male predominance.
Chondrosarcomas are sporadic, but they may develop from the malignant transformation of osteochondromas and enchondromas. Malignant transformation occurs in 5% of osteochondromas, either multiple or solitary forms.

Request for free sample report: https://www.delveinsight.com/report-store/chondrosarcoma-market

Some of the Chondrosarcoma Companies:

Agios Pharmaceuticals
Forma Therapeutics
Eli Lilly and Company
PharmaMar
And Many Others

Chondrosarcoma Drugs Covered:

AG-120
Olutasidenib
LY3410738
Trabectedin
And Many Others

Request for free sample report: https://www.delveinsight.com/report-store/chondrosarcoma-market

Microsatellite Stable Colorectal Cancer Market

Microsatellite stable colorectal cancer bears fewer signals that alert the immune system to cancer. So checkpoint inhibitors, such as nivolumab, have been unsuccessful in treating MSS colorectal cancer (CRC). Clinical trials have been going on to develop the promising drug for MSS colorectal cancer.

Some facts of Microsatellite Stable Colorectal Cancer Market Report are:

Approximately 15% of colorectal cancers (CRC) display MSI owing either to epigenetic silencing of MLH1 or a germline mutation in one of the mismatch repair genes MLH1, MSH2, MSH6 or PMS2.
According to DelveInsight, Microsatellite Stable Colorectal Cancer Market is expected to grow at CAGR of XX% during the forecast period.
Keytruda, Opdivo with or without Yervoy, and Braftovi in combination with Erbitux are recent additions to the Metastatic Colorectal Cancer treatment market.
Talking about gender-predisposition, CRC is the third most commonly diagnosed cancer in males and the second in females. It is most frequently diagnosed in people of age group 65–74.

Request for Free Sample Report: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market

Some of Microsatellite Stable Colorectal Cancer Companies in the market:

Gritstone Oncology
Merck Sharp & Dohme Corp.
Arrys Therapeutics
NeoImmuneTech
And Others

Request for Free Sample Report: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market

Microsatellite Stable Colorectal Cancer Drugs:

GRANITE
MK7123-034
NT-I7
TPST-149
And Many Others

Request for Free Sample Report: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market

Rituximab Biosimilars Insight

Rituximab is a type of antibody therapy, which can be used alone or with chemotherapy. They work in different ways to catch and attack the cells where cancer occurs. Rituximab targets and attaches to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells. Rituximab is used for treating certain types of cancer. It works by reducing or prohibiting the growth of cancer cells. This drug is also used for treatment of certain types of blood vessel disease, decrease the swelling of the blood vessels, and treat a specific skin condition.

Have a query? Ask our Experts @ https://www.delveinsight.com/report-store/rituximab-biosimilars-insight

Rituximab Biosimilars Drugs covered in the report:-

IBI-301
RGB 03
RITUMAX
ABP 798
AcellBia/Usmal
Blitzima/Truxima
BX 2336
DRL_RI
GP2013
HLX01
iBio Rituximab
IBPB 001RX
MK-8808
Ritemvia/Blitzima
Riximyo
RTXM83
Ruxience
AP 052
Retuxira
TL-011
RituxiRel
Kikuzubam
LBRx
DRL-rituximab
MG1106
GB-241
Rilast
HS 006
BX 2336
GNR-006

Have a query? Ask our Experts @ https://www.delveinsight.com/report-store/rituximab-biosimilars-insight

Scope of Rituximab Biosimilars report:

Major Players in Rituximab – 35+ key companies
Phases – 35+ products under different phases of clinical development
- Marketed stage products
- Late-stage products (BLA Filed and Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration

Route of Administration
- Subcutaneous
- Intravenous
- Molecule Type
Molecule types
- Monoclonal antibodies
- Peptide
- Protein
- Small molecule
- Product Type

Product Types

Mono
Combination
Mono/Combination

Have a query? Ask our Experts @ https://www.delveinsight.com/report-store/rituximab-biosimilars-insight

Pain Management Devices Market

Pain management is a field of medical science that makes it easier for people with chronic pain who suffer. Acute pain has a rapid onset of action, while chronic pain lasts for a prolonged period of time, causing it to to be managed. Pain management device is a medical system used to treat various forms of pain, such as neuropathic pain, cancer pain, nociceptive pain, musculoskeletal pain, and others.

Some key facts of the Pain Management Devices Market:

Global Pain Management Devices Market is expected to grow at a CAGR of 7.89% during the forecast period from 2021 to 2026.
The demand for Pain Management Devices is primarily motivated by the rise in prevalence of chronic pain, high prevalence of musculoskeletal disorders, surge in geriatric population, surge in awareness among people toward pain management devices, improved R&D investment to develop innovative products, and increasing cost of healthcare expenditure.
According to World Health Organization (2019), the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018.

View Report: https://www.delveinsight.com/report-store/pain-management-devices-market

Some of the Pain Management Devices Companies are:

St. Jude Medical, Inc.
Boston Scientific Corporation
Medtronic plc
Smiths Medical
Abbott
Nevro Corp.
Stimwave LLC
And Many More

Pain Management Devices Market Drivers

Growing need for long-term pain relief in the geriatric consumer
Large & rising population base of patients
Adverse effects of pain medications
Widely demonstrated effectiveness of pain management devices

View Report: https://www.delveinsight.com/report-store/pain-management-devices-market

22q11.2 Deletion Syndrome Market

22q11.2 Deletion Syndrome is a condition that develops because of chromosome defects and is a complex, multi-organ disorder noted for its varying severity and penetrance among those affected. As per several studies, it is the most common chromosomal microdeletion reported in humans.

Some facts of 22q11.2 Deletion Syndrome Market are:

In 2020, the total prevalent cases of 22q11.2 deletion syndrome were 196,476 in the 7MM. The United States, in the same year, accounted for 83,326 cases, the highest prevalence of 22q11.2 deletion syndrome cases in the 7MM, accounting for approximately 42% of the total 7MM cases in 2020.
Among the EU-5 countries, the highest number of cases of 22q11.2 deletion syndrome were in Germany and the least in Spain in 2020.
22q11.2 deletion syndrome is often underdiagnosed and misdiagnosed, as the symptoms vary from patient to patient. In the EU-5 countries, the total diagnosed prevalent cases of 22q11.2 deletion syndrome were 35,203 in 2020.
22q11.2 deletion syndrome is a multisystem disorder characterized by several physical, behavioral and psychiatric disorders. In the 7MM, of the focused age-group 6 to 12 and 13 to 17 years, the diagnosed prevalent cases of 22q11.2 deletion syndrome with Behavioral and Psychiatric Phenotypes were 36,702, in 2020.

View Report: https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market

Some of 22q11.2 Deletion Syndrome Companies are:

Zynerba Pharmaceuticals
Enzyvant
Roivant Sciences
Sumitomo Dainippon Pharma
And Many Others

Some of 22q11.2 Deletion Syndrome Therapies are:

Zygel (ZYN002)
RVT-802
And Many Others

View Report: https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market

Get in touch with our Business executive for Rich and Deep Healthcare Consulting Solutions

DelveInsight’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.

Some of Newly Launched Report:

Related Blogs:

About Delveinsight:

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter

DelveInsight’s Trending Reports 2022: Ehlers-Danlos Syndrome Market, X Linked Hypophosphatemia Market, Thyroid Eye Disease Market, Primoridal Dwarfism Market, Sialidosis Market.

Ehlers-Danlos Syndrome Market

Ehlers-Danlos syndrome (EDS) is a disease that weakens the connective tissues of your body. These are things like tendons and ligaments that hold parts of your body together. EDS can make your joints loose and your skin thin and easily bruised. It also can weaken blood vessels and organs.

Some facts of Ehlers-Danlos Syndrome Market Report are:

The combined prevalence of all types of Ehlers-Danlos syndrome appears to be at least 1 in 5,000 individuals worldwide.
Vascular EDS is reported to have a prevalence of 1 in 100,000 individuals, and cardiac-valvular EDS a prevalence of less than 1 in a million people.
The estimated prevalence for all EDS varies between 1/10,000 and 1/25,000, EDS type IV representing approximately 5 to 10% of cases.

View Report: https://www.delveinsight.com/report-store/ehlers-danlos-syndrome-market

Some of Ehlers-Danlos Syndrome Companies are:

Aventis Pharmaceuticals
EVAMED
Acer Pharma
And Many Others

View Report: https://www.delveinsight.com/report-store/ehlers-danlos-syndrome-market

Ehlers-Danlos Syndrome Therapies are:

Celiprolol
Irbesartan
And Many Others

X Linked Hypophosphatemia Market

X-linked hypophosphatemia is a hereditary renal phosphate-wasting disorder characterized by hypophosphatemia, rickets and/or osteomalacia, and diminished growth. Phosphate levels are low because phosphate is abnormally processed in the kidneys, which causes a loss of phosphate in the urine (phosphate wasting) and leads to soft, weak bones (rickets). XLH is usually diagnosed in childhood. Features include bowed or bent legs, short stature, bone pain, and severe dental pain. XLH is the most common form of hereditary hypophosphatemic rickets.

Some facts of X Linked Hypophosphatemia Market Report are:

According to study conducted by He ́le`ne et al., titled “Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms”, the estimated prevalence of X-linked hypophosphatemia was 4.8 per 100,000.
As per Endocrine Society, the Food and Drug Administration (FDA) estimates that XLH affects about 3,000 children and 12,000 adults in the United States
According to Phosphodiabetes E.V. Netzwerk Information Austausch, estimates that X-linked hypophosphatemia (XLH) is the most common form of vitamin D-resistant rickets and, with a prevalence of 4.8 cases per 100,000 individuals, is considered a rare disease.
The study by Riancho et al., titled “Osteomalacia and rickets” estimates that the prevalence of Hypophosphatemic rickets linked to the X chromosome due to a mutation in the PHEX gene is around 5 per 100,000.

View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market

Some of X Linked Hypophosphatemia Companies are:

Ultragenyx
Validus Pharmaceuticals
Prospec-Tany Technogene Ltd
Merck KGaA
Zeria Pharmaceutical Co., Ltd
Smith & Nephew
Narang Medical Limited
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
And Many Others

View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market

X Linked Hypophosphatemia Therapies are:

Burosumab
Crysvita
And Many Others

Thyroid Eye Disease Market

Thyroid eye disease (TED)—also known as Graves’ Orbitopathy or Ophthalmopathy—is an autoimmune condition. It occurs when the body’s immune system attacks the tissue surrounding the eye causing inflammation in the tissues around and behind the eye. It appears that the same antibody that can cause thyroid dysfunction may also have an “attraction”to tissuessurrounding the eyes causing the onset of Graves’ Ophthalmopathy. Moreover, the disease is categorized as mild, moderate, and severe.

Some of Thyroid eye disease Facts:

In a study by Zagaria et al. [2011], it was observed that approximately 25‐30% of patients with Graves’ disease have clinical evidence of Graves’ ophthalmopathy.
As per the study by Liaboe et al., titled “An Introductory Tutorial and Overview of Disease”, TED has a higher prevalence in women than men (16 per 100,000 vs. 3 per 100,000, respectively). Both men and women demonstrate a bimodal pattern of age of diagnosis(40–44 and 60–64 yearsin women; 45–49 and 65–69 years in men).
The study by Lazarus et al. titled “Epidemiology of Graves’ orbitopathy (GO and relationship with thyroid disease” estimates that Graves’ ophthalmopathy (GO) occurs mainly, but not exclusively, in patients with Graves’ disease. However, only about <50% of Graves’ patients have clinically apparent ophthalmopathy, where the approximate prevalence is 0.25%.
According to a review article titled “Epidemiology and Prevention of Graves’ Ophthalmopathy” by Wilmar et al., Graves’ ophthalmopathy is clinically relevant in approximately 50% of patients with Graves’ disease, and severe forms affects less than 5% of patients.

View Report: https://www.delveinsight.com/report-store/thyroid-eye-disease-market

Some of Thyroid eye disease Companies:

Immunovant Sciences
Horizon Therapeutics
And Many Others

Thyroid eye disease Drugs Covered:

IMVT‐1401
Teprotumumab
And Many Others

View Report: https://www.delveinsight.com/report-store/thyroid-eye-disease-market

Primoridal Dwarfism Market

Primordial dwarfism is a rare and often dangerous group of genetic conditions that result in a small body size and other growth abnormalities. Signs of the condition first appear in the fetal stage and continue through childhood, adolescence, and adulthood.

Some facts of Primordial Dwarfism Market Report:

Primordial Dwarfism Market size is expected to change for 7MM during the forecast period of 2018-30.
Its prevalence report estimates 4 million babies to die in the ﬁrst 4 weeks of life (the neonatal period) with almost 99 % of neonatal deaths (Lawn et al. 2011; Cous-ens et al. 1995).
The modern prevalence of MOPDII is unknown, but between 150 and 200 cases are reported worldwide each year (Bober and Jackson, 2017).
All types of primordial dwarfism are caused by changes in genes. Different gene mutations cause the different conditions that make up primordial dwarfism.
Primordial dwarfism can be difficult to diagnose. This is because the small size and low body weight could be a sign of other things, such as poor nutrition or a metabolic disorder.

To get more detailed insight on Primordial Dwarfism Market Report @Request for a Sample Report here: https://www.delveinsight.com/report-store/primordial-dwarfism-market

Some of Primordial Dwarfism Companies are:

GeneScience Pharmaceuticals
Merck
Genentech, Inc.
Pfizer
Novo Nordisk
EMD Serono
And Many Others

Primordial Dwarfism Therapies are:

Jintrolong® low dose group
Recombinant human growth hormone (r-hGH)
Somatropin
And Many Others

To get more detailed insight about Primordial Dwarfism Therapies @Request for a Sample Report here: https://www.delveinsight.com/report-store/primordial-dwarfism-market

Sialidosis Market

Sialidosis is characterized by a deficiency of the digestive enzyme, alpha-neuraminidase. The lack of this enzyme results in an abnormal accumulation of complex carbohydrates known as mucopolysaccharides, and of fatty substances known as mucolipids. Both of these substances accumulate in bodily tissues. There are four types of Sialidosis: Each type of Sialidosis is characterized by the age of onset and by the type of physical and mental manifestations of this disorder.

Some of Sialidosis facts:

As per ISMRD, Sialidosis is among the rarest Lysosomal Storage Diseases, affecting perhaps less than 1:4,000,000 worldwide and is thought to be more common in people with Italian ancestry.
As per the International Advocate for Glycoprotein Storage Diseases (ISMRD), Type I is the mildest form of Sialidosis, with a range of onset from anywhere between 8-25 years of age.
According to NORD, Sialidosis affects males and females in equal number.
The prevalence is estimated to be less than 1/1,000,000.

View Report: https://www.delveinsight.com/report-store/sialidosis-market

Get in touch with our Business executive for Rich and Deep Healthcare Consulting Solutions

Some of Newly Launched Report:

Related Blogs:

About Delveinsight:

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter

Anti-GBM Disease market size in the 7MM is expected to rise by 2030 with a CAGR of 22.2% during the study period (2018–2030), Estimates DelveInsight

Anti-Glomerular Basement Membrane (anti-GBM) disease (also known as Goodpasture syndrome or disease) is a rare but serious autoimmune disease that causes inflammation in the kidneys and lungs. Anti-GBM disease may affect only the kidneys; however, when it causes both kidney and lung disease, it is called Goodpasture’s syndrome. In anti-GBM disease, the immune system mistakenly makes “anti-GBM antibodies” that attack the lungs and kidneys, leading to bleeding and inflammation in the organs.

DelveInsight’s ‘Anti-GBM Disease Market Insights, Epidemiology, and Market Forecast 2030’ report delivers an in-depth understanding of the Anti-GBM disease, historical and forecasted epidemiology as well as the Anti-GBM Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

View Report: https://www.delveinsight.com/report-store/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights

Some facts of Anti-GBM Disease Market are:

Delveinsight Estimates that the highest cases of Anti-GBM Disease in the 7MM were in United States, followed by the Germany, France, the United Kingdom, Italy, Spain, and Japan in 2020.
According to DelveInsight, In the United States, the total number of incident cases of Anti-GBM Disease was 532 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
According to DelveInsight, In the year 2020, the total incident cases of Anti-GBM Disease were 522 cases in EU-5 which are expected to grow during the study period, i.e., 2018–2030.
According to DelveInsight, In Japan, the total number of incident cases of Anti-GBM Disease was 63 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.

To get detailed analysis of Anti-GBM Disease Market Report, Click Here @ https://www.delveinsight.com/sample-request/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights

Scope of the Anti-GBM Disease Market Report

The report covers the descriptive overview of Anti-GBM, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
Comprehensive insight has been provided into the Anti-GBM epidemiology and treatment in the 7MM.
Additionally, an all-inclusive account of both the current and emerging therapies for Anti-GBM is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of the Anti-GBM market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anti-GBM market.

Anti-GBM Disease Pipeline Drugs and Companies:

Idefirix (Imlifidase/HMed-IdeS): Hansa Biopharma
And Others

View Report: https://www.delveinsight.com/report-store/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights

Expert Analysis:

Increase in the geriatric population play an important role in the development and exacerbation of Anti-GBM therapeutics market. Due to the growing pace of the elder population, the market of Anti-GBM is expected to increase in the forecast period.
Despite having lots of diagnosis options there are high chances of patients getting delay in diagnosis for Anti-GBM can be observed and the possible hurdles might be the lack of proper understanding of the disease (Anti-GBM).
Among the emerging therapies, Hansa Biopharma’s Idefirix (Imlifidase/HMed-IdeS), appears to be the only drug which have the potential to transform the Anti-GBM Disease market owing to impressive clinical data.

To get detailed analysis of Anti-GBM Disease Market Report, Click Here @ https://www.delveinsight.com/sample-request/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights

Table of Contents:

1. Key Insights

2. Report Introduction

3. Anti-Glomerular Basement Membrane (anti-GBM) Disease Market Overview at a Glance

4. Executive Summary of Anti-Glomerular Basement Membrane (Anti-GBM) Disease

5. Epidemiology and Market Methodology

6. Disease Background and Overview

7. Diagnosis of Anti-GBM disease

8. Diagnostic Guidelines

9. Treatment of Anti-GBM disease

10. Treatment Guidelines

11. Epidemiology and Patient Population

12. Patient Journey Anti-GBM

13. Key Endpoints in Anti-GBM Disease Clinical Trials

14. Emerging Therapies

14.1. Idefirix (Imlifidase/HMed-IdeS): Hansa Biopharma

15. Anti-GBM Disease: 7 Major Market Analysis

16. Market Access and Reimbursement

17. KOL Views

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Unmet Needs

22. Appendix

23. DelveInsight Capabilities

24. Disclaimer

View Report: https://www.delveinsight.com/report-store/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Osteoarthritis Market is expected to showcase exceptional Growth by 2032 – Estimates DelveInsight | Key Companies- Novartis, Peptinov, 4P Pharma, Sorrento, Eupraxia, Biosplice, Ampio, Bone Therapeutics, & Others

Osteoarthritis, also known as the degenerative joint disease (DJD) is the most common form of arthritis. It occurs when the protective cartilage which cushions the ends of the bones wears over a period of time. The disease is likely to progress as people age. Inflammation and injury caused to the joint might lead to bony changes, deterioration of Tendons and ligaments and a breakdown of cartilage, resulting in pain, swelling, and deformity of the joint.

DelveInsight’s “Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Osteoarthritis, historical and forecasted epidemiology as well as the Osteoarthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

View Report: https://www.delveinsight.com/report-store/osteoarthritis-market

Some facts of Osteoarthritis Market Report:

According to the EULAR Study Group (2015), it was estimated that OA affects about 40 million people in Europe. It was relatively infrequent in people under the age of 40 years but increased definitely with age. Under the age of 45 women were less affected than males which reverse above the age of 45.
Osteoarthritis (OA) is the 4th leading cause of disability across the world and is thought to be the most prevalent of all musculoskeletal pathologies, affecting an estimated 10% of the world’s population over the age of 60.
According to Osteoarthritis Action Alliance, while there are estimated to be more than 100 types of arthritis, OA is the most common form of arthritis, affecting 32.5 million US adults. 43% of people with OA are 65 or older and 88% of people with OA are 45 or older. 62% of individuals with OA are women. Among people younger than 45, OA is more common among men; above age 45, OA is more common among women.
Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment can act as a market barrier.

Get More Detailed Insights into the Osteoarthritis Market Report: https://www.delveinsight.com/sample-request/osteoarthritis-market

Symptoms associated with osteoarthritis

Osteoarthritis symptoms tend to develop slowly and worsen gradually with time. The signs and symptoms of osteoarthritis include, pain as the affected joints might hurt as a result of movement, joint stiffness, tenderness, when the individual applies light pressure to or near it, loss of flexibility, grating sensation when the individual hears popping or crackling, bone spurs or extra bits of bone that feels like a hard lump and forms around the affected joint, swelling that might result due to soft tissue inflammation around the joint.

View Report: https://www.delveinsight.com/report-store/osteoarthritis-market

Osteoarthritis Diagnosis

Osteoarthritis is primarily a clinical diagnosis. However, plain radiography can be helpful in confirming the diagnosis and ruling out other pathology.34 MRI and computed tomography are rarely needed. There are certain plain radiographic findings characteristic of Osteoarthritis. Osteoarthritis often demonstrates joint space narrowing, osteophyte formation, subchondral sclerosis, and cysts.

Key Benefits of Osteoarthritis Market Report

The report provides an in-depth analysis of Osteoarthritis Market Size and Share till 2032 in the 7MM.
The report will help in developing business strategies by understanding the Osteoarthritis Market Trends, key players, and ongoing developments activities, that shape and drive the market growth in the upcoming years.
It covers Osteoarthritis’s current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.
The report provides a detailed assessment of the Osteoarthritis market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.

View Report: https://www.delveinsight.com/report-store/osteoarthritis-market

Osteoarthritis Pipeline therapies and Companies:

DK 004: Jiangsu Carephar Pharmaceutical
4P-004: 4P Pharma
LNA043: Novartis
LRX712: Novartis
X 0002: Techfields Pharma
DMI 9523: Ampio Pharmaceuticals
PPV-06: Peptinov
And Others.

Get More Detailed Insights into the Emerging Therapies & Key Companies: https://www.delveinsight.com/sample-request/osteoarthritis-market

The Osteoarthritis therapeutics market has a promising outlook with the emerging therapies, consisting of several Phase III and Phase II assets.

Osteoarthritis Market Drivers

Growing geriatric population and hence the rising prevalence of osteoarthritis
Favorable government policies to support the development of new therapies for the Osteoarthritis, and Others

Table of Content

1. Key Insights

2. Executive Summary

3. Osteoarthritis Competitive Intelligence Analysis

4. Osteoarthritis Market Overview at a Glance

5. Osteoarthritis Disease Background and Overview

6. Osteoarthritis Patient Journey

7. Osteoarthritis Epidemiology and Patient Population

8. Osteoarthritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Osteoarthritis Unmet Needs

10. Key Endpoints of Osteoarthritis Treatment

11. Osteoarthritis Marketed Products

12. Osteoarthritis Emerging Therapies

13. Osteoarthritis Seven Major Market Analysis

14. Attribute Analysis

15. Osteoarthritis Market Outlook (7 major markets)

16. Osteoarthritis Access and Reimbursement Overview

17. KOL Views on the Osteoarthritis Market.

18. Osteoarthritis Market Drivers

19. Osteoarthritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

View Report: https://www.delveinsight.com/report-store/osteoarthritis-market

About DelveInsight